Top

Welcome!

ABOUT US

FIND LABORATORIES

LABORATORY REGISTRATION

SUPPORT

Email

Cell Applications, Inc. Press Releases

Articles 2 | Case Studies 1 | Press Releases 5 | White Papers 0 | Events 0

Posted: 10/26/2016

Perineurial Fibroblasts and Schwann Cells Introduced at CAI, Oct 25, 2016

Today Cell Applications, Inc. announces the addition of two key Primary Cells of the nervous system: Rat Perineurial Fibroblasts (RPF) and Rat Schwann Cells (RSC), paired with their corresponding, optimized Media. RPF form a connective tissue compartment of the peripheral nerve called the perineurium, which wraps around fascicles to form a diffusion barrier. The perineurium protects nerve bundles, maintains endoneurial homeostasis and modulates external stretching forces on the nerve. RSC provide physical and chemical support for axons and neur

Today Cell Applications, Inc. announces the addition of two key Primary Cells of the nervous system: Rat Perineurial Fibroblasts (RPF) and Rat Schwann Cells (RSC), paired with their corresponding, optimized Media. RPF form a connective tissue compartment of the peripheral nerve called the perineurium, which wraps around fascicles to form a diffusion barrier. The perineurium protects nerve bundles, maintains endoneurial homeostasis and modulates external stretching forces on the nerve. RSC provide physical and chemical support for axons and neurons, critical for their morphology, survival and growth. Myelinating Schwann cells surround neurons to form an insulating sheath, important for propagation of action potentials along the axon. Studies also indicate Schwann cells promote neuronal restoration and experimental spinal cord regeneration.

Daniel Schroen, VP Sales & Marketing at Cell Applications adds, ?Nerve-related research continues to represent a highly active area of investigation. We are pleased to assist laboratory workers in these fields with a ready supply of quality controlled, rigorously characterized Nervous System Cells for their studies.?

Press & Media Relations Daniel Schroen, PhD VP, Sales & Marketing (858) 453-0848 d.schroen@cellapplications.com

Links:

https://www.cellapplications.com/nervous-system-cells

https://www.cellapplications.com/rat-perineurial-fibroblasts-rpf

https://www.cellapplications.com/rat-schwann-cells-rsc

Download Attachment

Posted: 10/04/2016

CAI Introduces Human Trabecular Meshwork Cells, Sep 27, 2016

Today Cell Applications, Inc. announces the addition of Human Trabecular Meshwork Cells to their Primary Eye Cells offering. Located near the base of the cornea, HTMC regulate eye pressure by controlling drainage of fluid from the eye and into tubes that ultimately flow to the bloodstream. Research using the cells aims to identify treatments that relax HTMC contraction to increase fluid outflow and lower eye pressure. Specific targeting of HTMC could also play a clinical role for therapeutic efficacy of nanoparticles using non-viral gene del

Today Cell Applications, Inc. announces the addition of Human Trabecular Meshwork Cells to their Primary Eye Cells offering. Located near the base of the cornea, HTMC regulate eye pressure by controlling drainage of fluid from the eye and into tubes that ultimately flow to the bloodstream. Research using the cells aims to identify treatments that relax HTMC contraction to increase fluid outflow and lower eye pressure. Specific targeting of HTMC could also play a clinical role for therapeutic efficacy of nanoparticles using non-viral gene delivery. "Damage, dysfunction and aging of the trabecular meshwork have clinical significance," says Dr. Daniel Schroen, a Vice President at Cell Applications, Inc. "Perhaps the most well-known example is Glaucoma, which causes irreversible blindness." In this disease, the trabecular meshwork becomes rigid, decreasing fluid outflow and causing an elevation on intraocular pressure. "Together with Corneal Epithelial Cells, the addition of HTMC strengthens the tools scientists utilize to address eye disorders, infections, diseases and malignancies," says Schroen.

Links:

https://www.cellapplications.com/trabecular-meshwork-cells-introduced

https://www.cellapplications.com/human-trabecular-meshwork-cells-htmc

https://www.cellapplications.com/eye-cells

Posted: 09/17/2016

Cell Applications, Inc. Introduces New Primary Cells

Asthma and COPD added to CAI's Cellular Disease Models, Aug 29, 2016 To facilitate research and airway drug development, Cell Applications now offers a panel of primary cells for use in Asthma and COPD studies. The cells, isolated from donors afflicted by the diseases, include Bronchial & Tracheal Epithelial Cells, Pulmonary & Lung Microvascular Endothelial cells and others. Multiple donor profiles and lots are available. Asthma and Chronic Obstructive Pulmonary Disease are both long-term diseases, where genetic, environmental and lifestyle

Asthma and COPD added to CAI's Cellular Disease Models, Aug 29, 2016

To facilitate research and airway drug development, Cell Applications now offers a panel of primary cells for use in Asthma and COPD studies. The cells, isolated from donors afflicted by the diseases, include Bronchial & Tracheal Epithelial Cells, Pulmonary & Lung Microvascular Endothelial cells and others. Multiple donor profiles and lots are available. Asthma and Chronic Obstructive Pulmonary Disease are both long-term diseases, where genetic, environmental and lifestyle factors cause the lungs and airways to deliver poor air flow. ?The resulting shortness of breath can be life-threatening in severe or end-stage cases,? says Dr. Daniel Schroen, Vice President of Sales and Marketing at Cell Application. ?There?s no cure for either, and asthma often begins in early childhood. We want to help life science researchers and pharmaceutical companies make strides in understanding, treating and managing the diseases.?

Cell Applications, Inc. Launches Human Dendritic Cells and Media, Aug 26, 2016

Today CAI introduced Human Dendritic Cells to their primary Blood Cell portfolio. Isolated from peripheral blood, the cells (HDC-PB for short) arise from a distinct hematopoietic lineage and help regulate the immune system. They mount adaptive immune responses to foreign antigens, prime T cells through antigen presentation and can induce tolerance to self-antigens. Academic & industrial research is driving toward new therapeutic approaches to modulate dendritic cells for vaccines and therapies to suppress pathogens, tumors and autoimmune disorders. According to Daniel Schroen, Vice President Sales and Marketing, ?Dendritic Cells complement and extend our other blood-derived cells, like T & B Lymphocytes, Hematopoietic Stem Cells, Mononuclear Cells, Monocytes, Macrophages and Microglial Cells.? Immunologists and others who study blood disorders can now source most blood cell types and media from one place. In addition to simplifying orders, lab workers can also benefit from the consistency of single-source products. ?That uniformity can improve the soundness of data comparing multiple cell types, for instance,? added Schroen. Currently undergoing an expansion phase, Cell Applications plans additional new primary cell products and services over the remainder of the year and into early 2017.

Daniel Schroen, PhD Vice President, Sales & Marketing Cell Applications, Inc. 5820 Oberlin Dr, Suite 101 San Diego, CA 92121 d.schroen@cellapplications.com 858.453.0848 (M 760.717.6055) www.cellapplications.com

Links:

https://www.cellapplications.com/new-airway-disease-models

https://www.cellapplications.com/dendritic-cells-introduced

https://www.cellapplications.com/new-airway-disease-models

https://www.cellapplications.com/dendritic-cells-introduced

Posted: 07/31/2016

New scaffold-free 3-D bioprinting method available for first time in North America

SAN DIEGO, CALIF. -- Feb. 3, 2016 -- Cell Applications, Inc. and Cyfuse Biomedical K.K. have announced that advanced tissue-engineering services are now available in North America using a groundbreaking new three-dimensional (3D) bioprinting approach called the "Kenzan Method." Utilizing Cyfuse Biomedical's Regenova® 3D Bio Printer, a state-of-the-art robotic system that fabricates 3D tissue from cells, Cell Applications has created a powerful pay-for-service bio-printing model that makes scaffold-free tissue available immediately to scientists

SAN DIEGO, CALIF. Feb. 3, 2016 Cell Applications, Inc. and Cyfuse Biomedical K.K. have announced that advanced tissue-engineering services are now available in North America using a groundbreaking new three-dimensional (3D) bioprinting approach called the "Kenzan Method." Utilizing Cyfuse Biomedical's Regenova® 3D Bio Printer, a state-of-the-art robotic system that fabricates 3D tissue from cells, Cell Applications has created a powerful pay-for-service bio-printing model that makes scaffold-free tissue available immediately to scientists in the U.S. and Canada for research use.

"In addition to customized cell isolation and assay services, Cell Applications is now able to provide researchers with an integrated cell-engineering solution that utilizes our expansive primary cell bank and the innovative Kenzan bioprinting method," said James Yu, Founder and CEO, Cell Applications. "Having the Regenova 3D Bio Printer at our San Diego headquarters with our vast array of primary cells is a powerful combination. We're very pleased to offer researchers an end-to-end, customized solution for creating scaffold-free, 3D-engineered tissues that reduce costs by minimizing the lengthy processes typical in pharmaceutical drug discovery."

"The Regenova 3D Bio Printer, combined with Cell Applications' comprehensive, high-quality primary cell bank, offers researchers streamlined access to a nearly limitless selection of three dimensional tissues including those mimicking blood vessels, human neural tissue and liver constructs," said Koji Kuchiishi, CEO, Cyfuse Biomedical. "The collective strengths of both our companies will serve the growing demand for viable engineered tissues and accelerate scientific discovery in North America, taking us one step closer to making regenerative medicine a reality."

Unlike other bioprinters currently available, the Regenova does not depend on scaffolding made of biomaterials such a collagen or hydrogel to construct 3D tissue. Instead, the instrument assembles three-dimensional macroscopic tissue by forming aggregates of cells, called spheroids, one at a time and lancing them onto a fine needle array. Pre-programmed software guides the collection of the spheroids, which can then be designed and constructed into small spheres, rods, sheets, tubes or other tissue configurations. As the engineered tissue fully matures during culture in a bioreactor chamber, the individual spheroids fuse with one another into any desired pattern within a range of approximately 10x10x10 millimeter at 500um resolution. Multiple pieces of bioprinted tissue can then be integrated together to form even larger constructs.

As the cells mature, they self-organize, promoting strong, reliable tissue that is further optimized by the design of the bio printer's needle array that allows for optimum circulation of culture medium. The Kenzan Method, meaning "needle array" in Japanese, is a much gentler approach and greatly increases the percentage of viable cells that survive within the 3D construction, in contrast to bioprinting and scaffolding techniques that utilize high-velocity liquid flow which often damage cells and yield insufficient cell numbers.

Using quality-controlled processes, Cell Applications offers more than one hundred types of human and animal primary cells, with nearly 900 configurations including cells freshly isolated or cryopreserved at early passage, with outstanding viability. Additional primary cell types can be isolated through the company's custom services program. The gentle Kenzan Method favors potentially delicate primary cells, which retain important properties of their original tissue systems without genetic or chemical modification, and are therefore often more physiologically relevant than immortalized cell lines. The company's partnership with Cyfuse Biomedical marks the first placement of the Regenova 3D Bio Printer outside of Japan, where Cyfuse has partnered with research universities to utilize the Kenzan Method.

Researchers at biopharmaceutical companies and academic research institutions have been utilizing or evaluating the Kenzan Method for research projects directed toward creating blood vessels, nerve, and functional liver-like tissues. Other anticipated applications include cardiac muscle and pancreatic islets, as well as spinal cord, urologic, trachea, skin and digestive tissues for regenerative medicine research, drug screening, and other basic researches in the pharmaceutical, biotechnology, cosmeceutical and academic research sectors.

###

To order custom-printed tissues using the Kenzan Method or to schedule a demonstration of the Regenova Bio Printer at Cell Applications headquarters in San Diego, California, please call 1-800-645-0848 or email info@cellapplications.com.

For information about renting or purchasing the Regenova instrument from Cyfuse Biomedical please contact its North American distributor AMUZA Inc. at 858-225-6869 or sazuma@amuzainc.com.

About Cell Applications, Inc.

Cell Applications, Inc. is a private company that specializes in primary cells, optimized culture media, reagents and custom-engineered cell and tissue solutions. Within its vast bank, the company holds more than 100 types of primary cells isolated from numerous tissues and species, providing the company's researchers and lab technicians access to nearly 900 configurations for research in the pharmaceutical, biotechnology, cosmeceutical and academic research sectors. Leveraging its custom cell-isolation services, Cell Application can purify, expand, freeze, document and test primary cells isolated from nearly any tissue or species.

Dr. Shinya Yamanaka, of the Frontier Medical Sciences at Kyoto University (Japan), used Cell Applications Human Dermal Fibroblasts in his groundbreaking discovery that mature cells can be reprogrammed to become induced pluripotent stem cells, or iPSC. Dr. Yamanaka's finding was hailed by TIME Magazine as the medical breakthrough of the year in 2007 and he was later awarded the Nobel Prize in Physiology or Medicine for the discovery in 2012.

In 2016, the company's headquarters in San Diego, California, became home to the first Regenova® 3D Bio Printer in North America through a partnership with Cyfuse Biomedical of Tokyo, Japan, making scaffold-free bioprinted tissue available in U.S. and Canada. Cell Applications offers comprehensive technical support for all its products and a global distribution network. For more information about Cell Applications call +1-858-453-0848 (international) or 1-800-645-0848 (from U.S. and Canada) or email info@cellapplications.com

About Cyfuse Biomedical

Cyfuse Biomedical, based in Tokyo, Japan, is the developer of the Regenova® 3D Bio Printer and the pioneer of the Kenzan bioprinting method. Recognizing the important role of regenerative medicine as society faces an aging population and an increase of of chronic disease, Cyfuse Biomedical is committed to developing new therapeutic approaches through innovative, bioengineering technologies that will make regenerative medicine a reality.

A "kenzan" is a base of needle-like prongs used to hold stalks of flowers and plants in Ikebana flower arrangements, the traditional Japanese floral art. From this, Cyfuse derived the name of the Kenzan Method, wherein cellular spheroids are skewered onto an array of needles in a pre-arranged design that matures into a three-dimensional, yet scaffold-free, tissue construct.

Cyfuse has partnered with several universities in Japan to utilize the Kenzan Method to construct tissue including blood vessels, cartilage and nerve tissue among others. Recently, the company placed the first Regenova 3D Bio Printer in North America through a partnership with Cell Applications, Inc. of San Diego, California. For more information visit http://www.cyfusebio.com.

Links:

http://www.eurekalert.org/pub_releases/2016-02/ppr-ns3020216.php

https://www.cellapplications.com/news-events-press-releases

Download Attachment

Posted: 07/31/2016

Cell Applications and StemoniX Accelerate Life Science Research with Mass Production of Human Induced Pluripotent Stem Cells

SAN DIEGO, June 22, 2016 /PRNewswire/ -- Cell Applications, Inc. and StemoniX announced a partnership that will allow them to produce up to one billion human induced pluripotent stem cells (HiPSC) from one lot within one week. These high-quality, consistent stem cells enable researchers to minimize their time laboriously preparing cells and spend more time doing meaningful, relevant research. This achievement was made possible through a proprietary, high-volume manufacturing process that produces affordable, reliable HiPSC for life science disc

SAN DIEGO, June 22, 2016 /PRNewswire/ Cell Applications, Inc. and StemoniX announced a partnership that will allow them to produce up to one billion human induced pluripotent stem cells (HiPSC) from one lot within one week. These high-quality, consistent stem cells enable researchers to minimize their time laboriously preparing cells and spend more time doing meaningful, relevant research. This achievement was made possible through a proprietary, high-volume manufacturing process that produces affordable, reliable HiPSC for life science discovery.

"The manual process of expanding stem cells is labor intensive and time consuming. By mastering high-volume biomanufacturing, we seek to revolutionize cell-based research and drug screening, leading to a new era of drug discovery and personalized, precision medicine," said Ping Yeh, StemoniX chief executive officer and co-founder. "Working with Cell Applications, we bring researchers access to high-volume, cost-effective HiPSC to help accelerate the understanding of various diseases and to identify potential compounds to treat them."

Lab workers at universities, life science institutes and pharmaceutical companies use HiPSC for basic cell biology research and genetic disease modeling, as well as for drug screening, development, efficacy and toxicity assessment. HiPSC typically are generated from adult human tissues?usually skin cells?that can be reprogrammed to an embryonic stem cell-like state thus avoiding the ethical considerations associated with human embryonic stem cells. Being donor/patient-specific, HiPSC open tremendous possibilities for a wide variety of personalized studies in biomedical research. High-volume biomanufacturing also has the potential to change the research paradigm by enabling investigators to save critical time and research dollars. These benefits will be realized by using HiPSC early in the discovery process to assess safety and efficacy issues of drug compounds in-vitro, rather than relying on costly, later-stage methods.

"Cell Applications is pleased that our strategic partnership with StemoniX will facilitate large-scale HiPSC production and enable more research labs, regardless of size, to afford the large cell amounts and consistent quality necessary to advance scientific research," said James Yu, Ph.D., co-founder and chief executive officer, Cell Applications.

About Cell Applications, Inc. Cell Applications, Inc. is a private company that specializes in primary cells, optimized culture media, reagents and custom-engineered cell and tissue solutions. Within its vast cell bank, the company holds more than 100 types of primary cells isolated from numerous tissues and species. This diversity provides laboratory staff access to nearly 900 cell ordering configurations, for basic life science studies in universities and non-profit research institutes, as well as pharmaceutical, biotechnology, consumer health and cosmetic companies. Human Dermal Fibroblasts from Cell Applications were instrumental in the groundbreaking discovery that mature cells can be reprogrammed to become induced pluripotent stem cells, or iPSC. The Human iPSC and associated culturing reagents, along with CAI's extensive primary cell product line, are available via direct contact or through the company's global distribution network. The Cell Applications Center for Primary Cell Technology and Innovation fosters cell-based discovery, and their San Diego, Calif. headquarters became home to the first Regenova® 3D Bio Printer in North America in early 2016. For more information about Cell Applications call +1-858-453-0848 (international) or 1-800-645-0848 (from U.S. and Canada) or email info@cellapplications.com.

About StemoniX StemoniX is leading the development and manufacturing of human induced pluripotent stem cells for academic and industrial pharmaceutical research and discovery applications, such as biologically accurate, miniaturized organ-like microtissues. Its biotechnology provides scientists the ultimate "in vitro" testing environment with standardized, easy-to-use, cost-effective access to relevant human microtissue for drug screening, toxicity and efficacy testing. In less than a year of operation, StemoniX developed the ability to scale stem cell technologies, brought them to a global sales and distribution agreement and generated a strong intellectual property portfolio. The company's products were recently qualified by one of the world's largest biopharma companies. Incorporated in Minnesota, the company is co-located in Minneapolis, Minn. and San Diego, Calif. StemoniX is revolutionizing drug discovery and making personalized medicine commercially relevant along the way. For more information about StemoniX, email info@stemonix.com.

Links:

http://www.prnewswire.com/news-releases/1-billion-cells-1-lot-1-week---cell-applications-and-stemonix-accelerate-life-science-research-with-mass-production-of-human-induced-pluripotent-stem-cells-300288887.html

https://www.cellapplications.com/news-events-press-releases

Download Attachment